Moderate to Severe Plaque Psoriasis Pipeline Analysis Report 2026

Report Coverage

The Moderate to Severe Plaque Psoriasis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into moderate to severe plaque psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for moderate to severe plaque psoriasis. The moderate to severe plaque psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The moderate to severe plaque psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with moderate to severe plaque psoriasis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to moderate to severe plaque psoriasis.

Read more about this report - Request a Free Sample

Moderate to Severe Plaque Psoriasis Pipeline Outlook

Moderate-to-severe plaque psoriasis is a chronic, systemic, immune-mediated skin disorder marked by thick, red, scaly plaques. It develops due to immune system overactivity, which accelerates skin cell turnover and triggers persistent inflammation, significantly impacting physical health, quality of life, and daily activities, often causing discomfort, itching, and social or psychological burdens for affected individuals.

Moderate-to-severe plaque psoriasis treatments include systemic therapies, phototherapy, biologics, and oral small molecules that target immune pathways, reduce inflammation, and improve skin clearance. In September 2022, the United States Food and Drug Administration approved Bristol Myers Squibb’s Sotyktu™ (deucravacitinib), a first-in-class, once-daily oral TYK2 inhibitor. Phase 3 POETYK PSO trials demonstrated superior efficacy, sustained skin clearance, and a favorable safety profile in adults.

Moderate to Severe Plaque Psoriasis Epidemiology

The pipeline is expanding in response to the growing global burden of the disease. According to the International Psoriasis Council, psoriasis affects approximately 2-3% of the global population, with higher prevalence in Western countries and bimodal incidence peaks at ages 35–44 and 65–74. As per Sanyam Mehta et al., 2025, plaque psoriasis accounts for 80–90% of all psoriasis cases. The Global Psoriasis Atlas reports a global adult lifetime prevalence of 0.59%, equivalent to approximately 29.5 million adults. Regional prevalence ranges from 0.14% to 3% in adults, and from 0.02% to 0.21% in children. These epidemiological insights support targeted drug development and pipeline prioritization.

Moderate to Severe Plaque Psoriasis – Pipeline Therapeutic Assessment

Moderate to Severe Plaque Psoriasis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 59%, covers a major share of the total moderate to severe plaque psoriasis clinical trials, driven by advanced efficacy data and larger patient populations. Phase II holds 20%, supported by promising safety and dose-optimization results. Phase IV accounts for 11%, reflecting real-world evidence. Phase I is 8%, guided by initial safety assessments, and early phase I is focused on first-in-human tolerability. These factors collectively strengthen clinical confidence and market potential.

Moderate to Severe Plaque Psoriasis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the moderate to severe plaque psoriasis pipeline analysis include small molecules, oligonucleotides, and peptides. The moderate to severe plaque psoriasis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for moderate to severe plaque psoriasis. Targeted oral peptide therapies are gaining attention in the pipeline. For instance, Icotrokinra (JNJ-2113) selectively blocks the IL-23 receptor and has demonstrated significant skin clearance and favorable safety in Phase 3 studies. Additionally, other investigational biologics and small molecules targeting IL-23, IL-17, and JAK pathways are being evaluated to improve efficacy and patient convenience.

Moderate to Severe Plaque Psoriasis Clinical Trials – Key Players

The EMR report for the moderate to severe plaque psoriasis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed moderate to severe plaque psoriasis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in moderate to severe plaque psoriasis clinical trials:

• Hansoh BioMedical R&D Company
• Oruka Therapeutics, Inc.
• Takeda
• CSPC Ouyi Pharmaceutical Co., Ltd.
• Janssen Research & Development, LLC
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• Beijing InnoCare Pharma Tech Co., Ltd.
• Usynova Pharmaceuticals Ltd.
• InventisBio Co., Ltd.
• Bristol-Myers Squibb
• Innovent Biopharmaceutical Technology (Hangzhou) Co., Ltd.
• Eli Lilly and Company

Moderate to Severe Plaque Psoriasis – Emerging Drugs Profile

Key Questions Answered in the Moderate to Severe Plaque Psoriasis Pipeline Insight Report

• Which companies/institutions are leading the moderate to severe plaque psoriasis drug development?
• Which company is leading the moderate to severe plaque psoriasis pipeline development activities?
• What is the current moderate to severe plaque psoriasis commercial assessment?
• What are the opportunities and challenges present in the moderate to severe plaque psoriasis pipeline landscape?
• What is the efficacy and safety profile of moderate to severe plaque psoriasis pipeline drugs?
• Which company is conducting major trials for moderate to severe plaque psoriasis drugs?
• Which companies/institutions are involved in moderate to severe plaque psoriasis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in moderate to severe plaque psoriasis?

Reasons To Buy This Report

The Moderate to Severe Plaque Psoriasis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for moderate to severe plaque psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into moderate to severe plaque psoriasis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Moderate to Severe Plaque Psoriasis Epidemiology Forecast

Plaque Psoriasis Pipeline Analysis Report

Chronic Plaque Psoriasis Pipeline Analysis Report